Effect of combination treatment of protocatechuic acid with 5-fluorouracil and oxaliplatin on colon cancer Caco-2 cell line

被引:4
|
作者
Yildiz, Fatma [1 ]
Eciroglu, Hamiyet [1 ]
Ovey, Ishak Suat [2 ]
Avnioglu, Seda [3 ]
机构
[1] Alanya Alaaddin Keykubat Univ, Vocat Sch Hlth Serv, Dept Med Lab Tech, Antalya, Turkiye
[2] Alanya Alaaddin Keykubat Univ, Fac Med, Dept Physiol, Antalya, Turkiye
[3] Alanya Alaaddin Keykubat Univ, Fac Med, Dept Anat, Antalya, Turkiye
关键词
Anticancer activity; Caco-2; Combination index; Dose reduction index (DRI); Matrix metalloproteinases (MMP); IN-VITRO ANTICANCER; LUNG; BREAST; MAPK;
D O I
10.56042/ijeb.v61i03.65610
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Among the most common antitumor drugs used in the treatment of colon cancer are 5-fluorouracil and oxaliplatin (5-FU and OXA). However, both these drugs have many side effects, and hence there is a need for new treatment\approach to reduce the side effects aas well as drug concentration. In this context, here, we investigated the effect of addition of protocatechuic acid (PCA) onto either monotherapies or combination therapies of 5-FU and OXA on the human colon cancer (Caco-2) cell line. In addition, we did evaluate the synergistic effect of PCA with 5-FU and OXA. Further, we determined the suppressive effects of different doses of PCA alone or in combination with 5-FU/OXA on cell proliferation after 24 and 48 hours. We identified a suppressive effect of PCA on cell viability at 48 h starting from the dose of 50 mu M Matrix metalloproteinase-2 (MMP-2) and MMP-9 gene expression levels and apoptotic effects showed significant increases and decreases depending on the dose and time applied in the experimental groups. The highest synergistic activity was seen at 2:1 concentration of 5-FU+ PCA. Our findings indicate the presence of the cytotoxic and apoptotic effects of PCA in Caco-2 cells at 48 h, increasing with a dose-and time-dependent manner.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 50 条
  • [21] Reduction of G(0) phase cells of colon cancer caco-2 cells may enhance 5-fluorouracil efficacy
    Ye, Lin
    Tao, Kaixiong
    Yu, Yang
    Wang, Guobin
    JOURNAL OF BIOMEDICAL RESEARCH, 2010, 24 (01): : 64 - 68
  • [22] ENDOCYTOSIS IN HUMAN COLON CANCER CELL-LINE CACO-2
    HEYMAN, M
    CRAINDENOYELLE, AM
    NATH, SK
    DESJEUX, JF
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1990, 14 (05): : 468 - 468
  • [23] Colorectal cancer metastasis resectability after treatment with the the combination of 5-fluorouracil, oxaliplatin and irinotecan
    Manzano, Jose L.
    Yuste, Ana L.
    Alonso, Vicente
    Vega, Maria E.
    Marcuello, Eugenio
    Carrato, Alfredo
    Martinez-Villacampa, Mercedes
    Tabernero, Jose M.
    Sastre, Javier
    Abad, Albert
    ANNALS OF ONCOLOGY, 2006, 17 : 283 - 284
  • [24] Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer
    Novarino, Anna
    Satolli, Maria Antonietta
    Chiappino, Isabella
    Giacobino, Alice
    Bellone, Graziella
    Rahimi, Farnaz
    Milanesi, Enrica
    Bertetto, Oscar
    Ciuffreda, Libero
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (01): : 44 - 48
  • [25] 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction
    Fakih, MG
    ONCOLOGY, 2004, 67 (3-4) : 222 - 224
  • [26] Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer
    Sandor, V
    LANCET, 1997, 350 (9087): : 1325 - 1326
  • [27] Sulphation of lithocholic acid in the colon-carcinoma cell line CaCo-2
    Halvorsen, B
    Kase, BF
    Prydz, K
    Garagozlian, S
    Andresen, MS
    Kolset, SO
    BIOCHEMICAL JOURNAL, 1999, 343 : 533 - 539
  • [28] Sulphation of lithocholic acid in the colon-carcinoma cell line CaCo-2
    Halvorsen, Bente
    Kase, Bengt Frode
    Prydz, Kristian
    Garagozlian, Sedegheh
    Andresen, Marianne S.
    Kolset, Svein Olav
    Biochemical Journal, 1999, 343 (pt 3): : 533 - 539
  • [30] Small-vessel vasculitis following treatment with combination 5-fluorouracil/folinic acid and oxaliplatin
    Hill, S. E.
    Phillips, R.
    Francis, N.
    Agnew, K.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2009, 34 (01) : 103 - 105